Immunogenic peptides solving the core problems of tumor and patient heterogeneity
We are changing the paradigm of cancer vaccine development
Treos Bio is a clinical stage company developing next generation of effective off-the-shelf peptide cancer vaccines based on a novel perspective on how HLA genes influence immune responses to cancer.
We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in genetically broad patient populations.
Our mission
More precise, effective, and accessible cancer vaccines
Our goal is to revolutionize cancer treatment by creating an integrated approach that harnesses the power of the immune system with unparalleled effectiveness. We aim to establish our PolyPEPI immunotherapy as the foundation of combination treatments, accessible to patients worldwide.
Our Science
PEPI Technology
PEPI stands for "Promiscuous Epitope"—a small protein fragment binding multiple MHC molecules of a person, thereby triggering exceptionally strong immune responses against tumor antigens —far surpassing the effectiveness of “common” epitopes.
By leveraging PEPIs, we develop treatments that more effectively target cancer cells, empowering the immune system to fight disease with greater accuracy and impact.
Why is PEPI Technology Unique?
Optimized Immune Targets
PEPIs bind multiple MHC molecules of a person, therefore trigger exceptionally strong immune responses against tumor antigens — far surpassing the effectiveness of “common” epitopes.
Clinical Outcome Correlation
Strong correlation observed between PolyPEPI induced immune responses and clinical outcomes in each of Treos’ clinical trials.
Novel Biomarker
PEPIs serve as genetic biomarkers using a simple saliva or blood sample, enabling rapid identification of likely responders.
Broad Patient Accessibility
PEPIs enable the development of off-the-shelf cancer vaccines that are effective across a genetically diverse patient population. The low cost and strong safety record makes PolyPEPI treatments accessible to patients worldwide.
Synergistic with Other Therapies
PEPIs enhance the efficacy of other anti-cancer treatments, such as chemotherapies, checkpoint inhibitors and others, without compromising their safety or toxicity profiles.
PEPI Technology is a transformative tool in the development of effective, accessible, and precise off-the-shelf cancer immunotherapies.
Lead product
PolyPEPI1018
Our lead product candidate PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine for colorectal cancer that has consistently demonstrated the ability to induce exceptionally robust immunological responses turning “cold” tumor to “hot” that associated with clinical benefits.
These effects were observed in both first-line maintenance MSS mCRC (OBERTO-101) and in late-stage MSS mCRC, in combination with standard-of-care chemotherapy treatments (OBERTO-201) and a PD-L1 inhibitor (OBERTO-301).
Better, Faster, Cheaper Immunotherapies
Contact Us
Reach out to discuss our drug development programs or collaboration opportunities—our team is ready to connect.